Zai Lab announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with r...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received orphan drug designation for anticancer ...
-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, a...
US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines ...
Novocure announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields...
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia ...
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on dev...
Collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancr...
-Massive Bio, a leader in AI-enabled oncology trial matching and patient access, and Prognos Health, a provider of actionable lab data, announced a...
Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics ...
Akeso, Inc.announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
© 2025 Biopharma Boardroom. All Rights Reserved.
